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ABSTRACT 
 
Synthesis of Charged Cyclodextrin Highly Soluble in Organic Solvents for 
Enantiomer Separations in Capillary Electrophoresis. (August 2005) 
Omar Maldonado, B.S., University of Puerto Rico 
 
Chair of Advisory Committee: Dr. Gyula Vigh 
 
 
 Synthesis of charged cyclodextrin highly soluble in organic solvents was 
made by exchanging the inorganic counter ion (Na+) of heptakis (2,3-di-O-
methyl-6-O-sulfo)-β-CD (Na7HDMS) with tetrabutylammonium (TBA+), to 
produce TBA7HDMS.  The same ion exchange was used to synthesize the TBA 
salts of the analogous CDs TBA6HxDMS and TBA8ODMS.  Indirect-UV 
detection capillary electrophoresis (CE) and 1H NMR were used as the 
characterization methods. 
 Separations of thirteen pharmaceuticals were made using TBA7HDMS as 
the chiral resolving agent in aqueous CE.  On the other hand, a set of twenty 
pharmaceuticals was used for the enantiomer separations in non-aqueous CE 
(NACE).  Comparison between the results obtained with TBA7HDMS in aqueous 
and non-aqueous CE were made.  In addition, comparison between the results 
obtained with TBA7HDMS and Na7HDMS in aqueous and non-aqueous CE were 
made as well. 
 
 
 
 
 iv
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my beloved family Oscar Maldonado, Julia E. Oquendo, Oscar Maldonado Jr. 
and Omayra Maldonado who deserve only the best from me. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v
ACKNOWLEDGMENTS 
 
 First, I give thanks to God for everything that He gives me and for 
everything that He takes away from me.   
 I would like to thank everyone that helped me to complete this work.  My 
special thanks to my family and the Pescadores members that always kept me 
focused on the important things in life.  In addition, I greatly appreciate all the 
ideas and help obtained from former and present members of the separation 
science group. 
 Finally, I give thanks to my advisor Dr. Gyula Vigh, for all the time he 
dedicated to me and my project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi
TABLE OF CONTENTS 
 
   Page 
ABSTRACT ...................................................................................................       iii 
 
DEDICATION ...............................................................................................        iv 
 
ACKNOWLEDGMENTS ...............................................................................         v 
 
TABLE OF CONTENTS................................................................................        vi 
 
LIST OF FIGURES ........................................................................................      viii 
 
LIST OF TABLES ...........................................................................................     xii 
 
CHAPTER 
 
I INTRODUCTION ...............................................................................         1 
 
1.1  Enantiomeric separations............................................................         1 
1.2  CDs as chiral resolving agents for CE ........................................         4 
1.3  Non-aqueous CE enantiomer separation....................................       12 
1.4  Purpose of this thesis project ......................................................       13
 
II SYNTHESIS OF THE TETRABUTYLAMMONIUM SALT OF          
       HEPTAKIS (2,3-DI-O-METHYL-6-O-SULFO)-β-CYCLODEXTRIN....       15 
 
2.1 Introduction ..................................................................................       15 
       2.1.1 Synthesis of intermediate I, heptakis(6-O-      
               tert-butyldimethylsilyl)-β-CD ................................................       18 
       2.1.2 Synthesis of intermediate II, heptakis(2,3-di-O-methyl-6-O-       
               tert-butyldimethylsilyl)-β-CD ................................................       18 
       2.1.3 Synthesis of intermediate III, heptakis(2,3-di-O-methyl)-β-        
               CD.......................................................................................       18 
       2.1.4 Synthesis of intermediate IV, the sodium salt of heptakis        
               (2,3-di-O-methyl-6-O-sulfo)-β-CD........................................       19 
2.2 Materials and methods.................................................................       19 
2.3 Results and discussion ................................................................       21 
       2.3.1 Characterization of TBA7HDMS .........................................       21 
       2.3.2 Characterization of the tetrabutylammonium salt of hexakis      
               (2,3-di-O-methyl-6-O-sulfo)-α-CD .......................................       28 
 
 vii
CHAPTER                                                                                                      Page 
 
       2.3.3 Characterization of the tetrabutylammonium salt of octakis     
               (2,3-di-O-methyl-6-O-sulfo)-γ-CD .......................................        28 
 
III ENANTIOMER SEPARATIONS IN AQUEOUS CAPILLARY    
        ELECTROPHORESIS WITH HEPTAKIS (2,3-DI-O-METHYL-6-O-  
        SULFO)-β-CYCLODEXTRIN TETRABUTYLAMMONIUM SALT .....        34 
 
3.1  Introduction ................................................................................        34 
3.2  Materials and methods...............................................................        37 
3.3  Enantiomer separations in low pH aqueous BGE using       
       TBA7HDMS as the chiral resolving agent...................................        38 
3.4  Comparison of enantiomer separations using TBA7HDMS and   
       Na7HDMS as the chiral resolving agent in low pH aqueous           
       BGEs..........................................................................................        58 
 
IV ENANTIOMER SEPARATIONS IN NON-AQUEOUS CAPILLARY 
        ELECTROPHORESIS WITH HEPTAKIS (2,3-DI-O-METHYL-6-O-  
        SULFO)-β-CYCLODEXTRIN TETRABUTYLAMMONIUM SALT .....        64 
 
4.1  Introduction ................................................................................        64 
4.2  Materials and methods...............................................................        67 
4.3  Enantiomer separations in acidic methanolic BGE using      
       TBA7HDMS as the chiral resolving agent...................................        68 
4.4  Comparison of enantiomer separations using TBA7HDMS as            
       the chiral resolving agent in aqueous and acidic methanolic           
       BGEs..........................................................................................        85 
4.5  Comparison of enantiomer separations using TBA7HDMS and    
       Na7HDMS as the chiral resolving agents in acidic methanolic         
       BGE ...........................................................................................        90 
 
V CONCLUSIONS................................................................................        97 
 
REFERENCES .............................................................................................     101 
 
APPENDIX A: SYNTHESIS PROTOCOL FOR TBA7HDMS............................. 106 
 
VITA..............................................................................................................     108 
     
 
 
 
 viii
LIST OF FIGURES 
 
FIGURE                                                                                                          Page 
 
      I-1   Structure of native CDs ................................................................         5 
 
      I-2   Ionoselective separation of a weak base: Selectivity surface as            
             a function of the charged CD concentration and the pH of the          
             BGE .............................................................................................         9 
 
      I-3   Desionoselective separation of a weak base: Selectivity surface               
             as a function of the charged CD concentration and the pH of the     
             BGE .............................................................................................       10 
 
      I-4   Duoselective separation of a weak base: Selectivity surface as             
             a function of the charged CD concentration and the pH of the              
             BGE .............................................................................................       11 
 
     II-1   Synthetic scheme of TBA7HDMS .................................................       16 
 
    II-2   Synthesis of the tetrabutylammonium salts of hexakis(2,3-di-O-                 
            methyl-6-O-sulfo)-α-CD and octakis(2,3-di-O-methyl-6-O-sulfo)-               
            γ-CD ..............................................................................................       17 
 
    II-3   Indirect-UV detection CE electropherograms of TBA7HDMS  
            (1g batch) ......................................................................................       22 
 
    II-4   1H NMR in D2O of TBA7HDMS (1g batch). ....................................       23 
 
    II-5   Indirect-UV detection CE electropherograms of TBA7HDMS  
            (10g batch) ....................................................................................       24 
 
    II-6   1H NMR in D2O of TBA7HDMS (10g batch) ..................................       25 
 
    II-7   Indirect-UV detection CE electropherograms of TBA7HDMS  
            (25g batch) ....................................................................................       26 
 
    II-8   1H NMR in D2O of TBA7HDMS (25g batch) ..................................       27 
 
    II-9   Indirect-UV detection CE electropherograms of TBA6HxDMS  
            (1g batch) ......................................................................................       29 
 
  II-10   1H NMR in D2O of TBA6HxDMS (1g batch) ...................................       30 
 ix
FIGURE                                                                                                      Page 
 
  II-11   Indirect-UV detection CE electropherograms of TBA8ODMS  
            (1g batch) ......................................................................................       32 
 
  II-12   1H NMR in D2O of TBA8ODMS (1g batch). ...................................       33 
 
   III-1   Contribution of the TBA7HDMS concentration to the viscosity of          
            the aqueous BGE..........................................................................       47 
 
   III-2   Absolute viscosity of the aqueous BGE at different TBA7HDMS 
             concentrations..............................................................................       48 
 
   III-3   Effective mobility (top panel) and separation selectivity plots                   
            (bottom panel) for the weakly binding analyte ketamine (B22) in                    
            low pH aqueous BGE....................................................................       49 
 
   III-4   Effective mobility (left panels) and separation selectivity plots                 
            (right panels) for the moderately strongly binding analytes B34           
            and B58 in low pH aqueous BGE..................................................       50 
 
   III-5   Effective mobility (left panels) and separation selectivity plots                      
            (right panels) for the strongly binding analytes B21, B31, B42              
            and Tryp in low pH aqueous BGE.................................................       52 
 
   III-6   Separation selectivity plots of N25 and N26 using TBA7HDMS as        
            the chiral resolving agent in low pH aqueous BGE .......................       55 
 
   III-7   Electropherograms of weak basic and ampholytic enantiomers            
            at low pH aqueous BGE using TBA7HDMS as the chiral resolving          
            agent .............................................................................................       56 
 
   III-8   Electropherograms of neutral enantiomers at low pH aqueous         
            BGE using TBA7HDMS as the chiral resolving agent....................       57 
 
   III-9   Comparison between the contribution of TBA7HDMS and    
            Na7HDMS concentration to the viscosity of the BGE ....................       59 
 
 III-10   Comparison of the absolute viscosity of the BGEs at different   
            TBA7HDMS and Na7HDMS concentrations...................................       60 
 
 III-11   Comparison of the mobility (left panel) and separation selectivity      
            plots (right panel) for N21, (N25), (N26) and (N27) when  
            TBA7HDMS and Na7HDMS were used in low pH aqueous BGE ..       62 
 x
FIGURE                                                                                                      Page 
 
 III-12   Comparison of the mobility (left panel) and separation selectivity     
            plots (right panel) for isoproterenol (B21), tryptophan (Tryp),   
            norephedrine (B34) and tetrahydrozoline (B54) when            
            TBA7HDMS and Na7HDMS were used in low pH aqueous BGE ..       63 
 
  IV-1   Electropherograms of some weak basic and ampholytic             
            enantiomers at acidic methanolic BGE using TBA7HDMS as the             
            chiral resolving agent ....................................................................       76 
 
  IV-2   Contribution of the TBA7HDMS concentration to the viscosity of           
            the acidic methanolic BGE ............................................................       79 
 
  IV-3   Absolute viscosity of the acidic methanolic BGE at different   
           TBA7HDMS concentrations ............................................................       80 
 
  IV-4   Effective mobilities as a function of TBA7HDMS concentration for           
            all the twenty enantiomers which are strongly binding analytes. ...       82 
 
  IV-5   Effective mobility (left panels) and separation selectivity plots                     
            (right panels) of 4-chloroamphetamine (B13) and ketotifen (B23)             
            when TBA7HDMS was used in acidic methanolic BGE.................       83 
 
  IV-6   Effective mobility (left panels) and separation selectivity plots                   
            (right panels) of propranolol (B42) and verapamil (B54) when   
            TBA7HDMS was used in acidic methanolic BGE. .........................       84 
 
  IV-7   Comparison of the mobility (top panel) and separation selectivity   
            (bottom panel) for ketamine (B22) when TBA7HDMS was used             
            in aqueous and non-aqueous BGEs. ............................................       86 
 
  IV-8   Comparison of the mobility (top panel) and separation selectivity   
            plots (bottom panel) for norephedrine (B34) and tetrahydrozoline    
            (B58) when TBA7HDMS was used in aqueous and non-aqueous   
            BGEs.............................................................................................       88 
 
  IV-9   Comparison of the mobility (top panel) and separation selectivity   
            plots (bottom panel) for isoproterenol (B21), metoprolol (B31),   
            propranolol (B42) and tryptophan (Tryp) when TBA7HDMS was       
            used in aqueous and non-aqueous BGEs.....................................       89 
 
 
 
 xi
FIGURE                                                                                                      Page 
 
IV-10   Comparison between the contribution of TBA7HDMS and   
            Na7HDMS concentration to the viscosity of the non-aqueous            
            BGE ..............................................................................................       91 
 
IV-11   Comparison of the absolute viscosity of the non-aqueous BGEs at   
            different TBA7HDMS and Na7HDMS concentrations.....................       92 
 
IV-12   Comparison of the mobility (top panel) and separation selectivity     
            plots (bottom panel) for isoproterenol (B21), metaproterenol    
            (B30), oxyphencyclimine (B36) and propranolol (B42) when  
            TBA7HDMS and Na7HDMS were used in NACE...........................       93 
 
IV-13   Comparison of the mobility (top panel) and separation selectivity   
            plots (bottom panel) for 4-chloroamphetamine (B13) and      
            ketotifen (B23) when TBA7HDMS and Na7HDMS were used in     
            NACE. ...........................................................................................       96 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xii
LIST OF TABLES 
 
 
TABLE                                                                                                            Page 
 
   III-1   Enantiomers analyzed in aqueous BGE .......................................       35 
 
   III-2   Enantiomer separation data in low pH aqueous BGE...................       39 
 
   IV-1   Enantiomers analyzed in non-aqueous BGE................................       65 
 
   IV-2   Enantiomer separation data in acidic methanolic BGE.................       69 
 
 
 
 1
CHAPTER I 
INTRODUCTION 
 
1.1 Enantiomeric separations 
The separation of enantiomers is vital in the pharmaceutical, chemical 
and biological fields.  The stereochemistry of such compounds can affect their 
biological activities, therefore method development for their purification and 
separation is of continued interest.  In order to achieve enantiomeric separation, 
a chiral resolving agent must be used.  Some common techniques for the 
separation of enantiomers are gas chromatography (GC) which uses the chiral 
resolving agent in the stationary phase [1-3], high performance liquid 
chromatography (HPLC) which uses the chiral resolving agent either in the 
stationary phase or in the mobile phase or both [4], and capillary electrophoresis 
(CE) which uses a background electrolyte (BGE) that contains the chiral 
resolving agent dissolved in a buffer solution [5-7].  From all the techniques, CE 
stands out due to its short analysis time, high efficiency, simplicity and low 
material consumption.  Since CE does not use a stationary phase, band 
broadening problems related to mass transfer to the stationary phase are 
minimal compared to HPLC and GC. 
In order to achieve enantiomeric separation in CE, each enantiomer has  
____________ 
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to complex differently with the chiral resolving agent to form two different 
diasteromeric complexes with different hydrodynamic volumes.  Therefore, the 
diasteromeric complexes will be separated by their differences in the 
electrophoretic velocities when the electric field is applied along the capillary [7-
14].  The observed electrophoretic velocity (vobs) of the enantiomer is defined in 
equation 1 [15]. 
         vobs = Eappl x µobs                               (1) 
where Eappl is the applied electric field strength and µobs is the observed 
electrophoretic mobility of the enantiomer which can be further described by 
equation 2 as the sum of the effective electrophoretic mobility (µeff) of the 
enantiomer and the electroosmotic flow mobility (µeo). 
µobs = µeff + µeo                              (2) 
Separation selectivity (α) for the enantiomers is defined as the ratio of the 
effective mobility of the faster enantiomer (µ1eff) over the effective mobility of the 
slower enantiomer (µ2eff) (equation 3). 
         α = µ1eff / µ2eff                          (3) 
An important parameter in the separation of enantiomers is the normalized 
electroosmotic flow (β) which is defined as the ratio between the electroosmotic 
flow and the effective mobility of the slower enantiomer (equation 4). 
         β = µeo / µ2eff                     (4) 
 Optimization of the separation selectivity can be accomplished by varying 
the pH, temperature, concentration of the organic modifier and the concentration 
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of the chiral resolving agent in the BGE [7-14,16-19].  On the other hand, 
optimization of resolution can be obtained by adjusting the electroosmotic flow 
mobility to be closer, but opposite in sign to the magnitude of the effective 
mobility of the slower enantiomer giving a β value closer to negative one [20-22].  
This can be done by using coated capillaries and/or by manipulating the 
viscosity of the BGE with the addition of hydroxymethylcellulose or other 
viscosity modifiers.   
Resolution is described by equation 5 
           
 Rs = 
eff
2
3eff
1
3
eff
2
eff
1
)zβ)abs((1α)zβ)abs((α
zzβ)abs(1β)abs(α1)abs(α
T8
E
+⋅++
++−
∗
k
le
o                  (5)    
 
eo is the fundamental charge, k is the Boltzman constant and zeff is the effective 
charge of the analyte.  Having a β value equal to negative one will increase the 
resolution to an infinitely high value.  This is true only if the separation selectivity 
(α) is not unity.  This idea was first discussed in what is known as the chiral 
resolving agent migration model (CHARM) [5, 9, 18-20].  According to the 
predictions of the CHARM model, resolution can be increased by increasing the 
applied potential (the multiple of the capillary length (l) and the increasing 
applied electric field, E) and decreasing temperature (T) which will increase 
complexation between the chiral resolving agent and the enantiomer.  In 
addition, resolution is dependent on the charge state of the enantiomers, the 
concentration and charge state of the cyclodextrin and the electroosmotic flow. 
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Since the interaction between the chiral resolving agent and the analyte is 
crucial to the separation of the enantiomers, choosing the right chiral resolving 
agent may be the difference between separation and no separation.  Some 
chiral resolving agents that are available are: crown ethers, macrocyclic 
antibiotics, chiral micelles, proteins, oligo- and polysaccharides and the most 
popular of all, cyclodextrins (CDs) [5, 7, 23-26]. 
 
1.2 CDs as chiral resolving agents for CE 
Native CDs are cyclic oligosaccharides formed by glucopyranose units 
attached to each other by α-1,4 glycosidic bonds creating a truncated cone 
shape (Figure I-1).  Depending on the number of glucopyranose units in the ring, 
the CD will be called alpha CD (α-CD, 6 units), beta CD (β-CD, 7 units) or 
gamma CD (γ-CD, 8 units).  CDs offer three major sites to interact with the 
analyte: i) the internal cavity which is made of the carbons in the glucose units 
(hydrophobic site), ii) the achiral face where the primary alcohol groups are 
located (C6 in the glucose unit, hydrophilic sites), iii) the chiral face where the 
secondary alcohol groups are located (C2 and C3 in the glucose unit, hydrophilic 
sites).  Some disadvantages of native CD are its poor solubility and limited types 
of intermolecular interactions (hydrogen-bonding and Van der Waals).  In order 
to overcome these disadvantages, researchers have been interested in the  
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Figure I-1. Molecular structure of native CDs [27]. 
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modification of CDs by substituting the hydroxyl groups attached to C2, C3 and 
C6 with different functional groups.  Since β-CD offers, lower cost and greater 
commercial availability compared to α-CD and γ-CD, its derivatives are more 
popular.  A wide variety of CD derivatives are available and are generally 
classified into neutral and charged CDs. 
Some neutral CD derivatives have been synthesized by substituting 
acetyl, benzyl, hydroxypropyl or methyl groups for the hydroxyl groups at the C2, 
C3 and/or C6 positions of the CDs [28, 29].  These CD derivatives offer different 
types of intermolecular interactions which lead to different stereoselectivities; 
however, they can only separate charged enantiomers and are not suitable for 
the separation of neutral enantiomers.   
Charged CD derivatives were introduced in order to expand their 
applicability to the separation of neutral enantiomers.  These ionic CDs can be 
made by substituting the hydroxyl groups in the C2, C3 and C6 positions with 
weakly or strongly acidic or basic functional groups.  Some examples of weakly 
acidic and basic functional groups are carboxylic acid groups and alkylamino 
groups.  Since the charge states of these functional groups are pH dependent, 
method development for the separation of enantiomers is more complicated as 
separation selectivity is pH dependent as well. 
On the other hand, strongly acidic and basic functional groups, such as 
sulfate and quaternary ammonium groups are pH independent since they are 
permanently charged through the entire working pH range (pH 2-12).  Sulfated 
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CD derivatives are preferred over the quaternary ammonium CD derivatives 
because positively charged CDs have been shown to bind to the wall of the 
commonly used fused silica capillaries which contain dissociated silanol groups 
[30].  This will lead to an increment in band broadening due chromatographic 
retention.  Capillary coating (e.g., polyacrylamide) had been successfully used to 
overcome this problem [31]; however, this is not required when negatively 
charged CD derivatives are used [32].   
In agreement with the information mentioned above, sulfated β-CD 
derivatives are the cyclodextrins of choice of those which are commercially 
available.  Unfortunately, most of these derivatives are found as isomeric 
mixtures with a certain average degree of substitution.  There are several 
problems with using isomeric mixtures including: i) the isomeric mixture 
composition can change from batch to batch, which requires optimization of the 
separation every time a new batch is synthesized or purchased; ii) since the 
chiral selectivity of the CD depends on how many substituents are attached to 
the CD and where they are located, the separation selectivity can be increased, 
reduced, or in the worst case, eliminated by having the same selectivity for both 
enantiomers [33]; iii) due to the different isomers, kinetic band broadening may 
happen when differences in the complexation rates are presents [34]; iv) it’s 
almost impossible to characterize the complexes and to perform studies at the 
molecular level with an isomeric CD mixture; v) it is impossible to predict any  
result a priori with such complex mixtures. 
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On the other hand, single-isomer sulfated β-CD derivatives have proven 
to be the solution for all the problems that come with the use of randomly 
substituted materials.  Characterization and applicability in the pharmaceutical 
field have been reported for single-isomer sulfated β-CD [34-43].  Enantiomer 
separations using single-isomer sulfated β-CD derivatives follow the behavior 
predicted by the CHARM model.  This model predicts that there are three types 
of enantiomer separations for the weak electrolytes: i) ionoselective; ii) 
desionoselective and iii) duoselective separations.  In the ionoselective 
separation (Figure I-2), the chiral resolving agent complexes selectively with the 
ionic form of the enantiomer.  On the other hand, desionoselective separation 
(Figure I-3) occurs when the chiral resolving agent complexes selectively with 
the neutral form of the enantiomer.  Finally, duoselective separation (Figure I-4) 
happens when the chiral resolving agent complexes selectively with both the 
ionic and nonionic forms of the enantiomers [8, 9].  This clearly indicates that the 
best separation selectivity can be found by performing the enantiomer 
separations using only a low pH BGE and a high pH BGE. 
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Figure I-2. Ionoselective separation of a weak base: Selectivity surface as a 
function of charged CD concentration and the pH of the BGE [9]. 
 
 
 
 
 
 10
 
 
Figure I-3. Desionoselective separation of a weak base: Selectivity surface as a 
function of charged CD concentration and the pH of the BGE [9]. 
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Figure I-4. Duoselective separation of a weak base: Selectivity surface as a 
function of charged CD concentration and the pH of the BGE [9]. 
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1.3 Non-aqueous CE enantiomer separation 
A wide variety of solvents have been reported to be suitable as the main 
components of BGEs in CE.  Aqueous BGEs have been extensively used since 
water has low viscosity, high relative permittivity, low volatility, low UV-cutoff and 
dissolves most analytes.  On the other hand, there are many other solvents 
(organic solvents) that meet these criteria such as: i) acetonitrile [44-46]; ii) 
amides such as formamide [47-50], N-methylformamide [51, 49, 52, 53], N, N-
dimethylformamide [49]; and, most commonly used, methanol [41, 45, 53-64].  
Non-aqueous CE (NACE) separation has been of interest since it complements 
and sometimes improves separations obtained in aqueous CE.  For example, 
NACE offers a low conductivity media which means that a higher potential can 
be used, therefore faster analysis with higher resolution can be achieved.  In 
addition, solubility is obtained for the water-insoluble analytes. Moreover, 
separation selectivity may improve due to the lower dielectric constant of the 
solvent which provides a different media where intermolecular interactions that 
were not present or were weak (negligible) in aqueous media can be observed.  
On the other hand, interactions between the analyte and the chiral resolving 
agent are usually weakened in NACE, lowering the formation constant of the 
complex.  Finally, NACE extends the applicability of CE by coupling it to mass 
spectrometry (CE-MS) which has become a very powerful technique [49, 65-69].   
Although NACE (hydro-organic) enantiomer separations with CDs have 
been used for more than a decade, the interest of using pure non-aqueous 
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solvents as BGEs has been growing recently.  However, progress has been 
limited due to the poor solubility of charged cyclodextrins in an organic media.   
 
1.4 Purpose of this thesis project 
 Enantiomer separations by CE have been very interesting to separation 
scientists.  So far there is no way to know a priori what is the right chiral 
resolving agent for a particular enantiomer.  Therefore, more studies concerning 
chiral selectivity are needed in order to understand such systems more and to 
be able make predictions efficiently. 
 As mentioned before, single-isomer sulfated β-CD has been used 
successfully for enantiomer separations and it is preferred over the randomly 
substituted sulfated β-CDs, since the single-isomer simplifies the system 
studied.  Due to the poor solubility of the single-isomer sulfated β-CD in organic 
solvents, the synthesis of a charged CD soluble in organic solvent is needed.  It 
has been proved that the solubility of the charged CD in an organic solvent 
increases significantly by exchanging the inorganic counter ion of the charged 
CD with an organic counter ion.   
A very stable and well characterized single-isomer sulfated β-CD has 
been chosen for further derivatization.  It is the sodium salt of the single-isomer 
heptakis(2,3-di-O-methyl-6-O-sulfo)-β-CD (Na7HDMS). This particular CD has 
been successfully used for the separation of the enantiomers of pharmaceuticals 
in aqueous and non-aqueous BGEs.  It is the aim of this project to investigate 
 14
the effect on the chiral selectivity and the solubility of the new derivative 
TBA7HDMS by exchanging the sodium counter ion of Na7HDMS with the 
tetrabutylammonium counter ion.  In order to be able to make any comparison of 
the results obtained with TBA7HDMS, the chiral drugs that were chosen in this 
project were previously analyzed by Na7HDMS using aqueous BGE and non-
aqueous BGE (methanol as the solvent). 
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CHAPTER II 
SYNTHESIS OF THE TETRABUTYLAMMONIUM SALT OF 
HEPTAKIS (2,3-DI-O-METHYL-6-O-SULFO)-β-CYCLODEXTRIN 
 
2.1 Introduction 
 The synthesis of the tetrabutylammonium salt of heptakis (2,3-di-O-
methyl-6-O-sulfo)-β-cyclodextrin (TBA7HDMS) was synthesized by adding one 
more step (ion exchange) to the reported [35] synthesis of the sodium salt of 
heptakis (2,3-di-O-methyl-6-O-sulfo)-β-cyclodextrin (Na7HDMS).  To obtain the 
final product several intermediates have been synthesized  and purified using 
modified procedures of the synthesis reported by Takeo [27] and well 
characterized by reverse phase-HPLC (RP-HPLC), CE, nuclear magnetic 
resonance (NMR) spectroscopy and MS.  The whole synthesis scheme consists 
of five steps as shown in Figure II-1.  Once TBA7HDMS was successfully made, 
the same procedure was used for the synthesis of TBA6HxDMS (α-CD) and 
TBA8ODMS (γ-CD) derivatives (Figure II-2). The first four steps of Figure II-1 are 
explained below which show the preparation of the sodium salt of heptakis (2,3-
di-O-methyl-6-O-sulfo)-β-CD (Na7HDMS) which were previously made in our 
laboratories and was utilized as the starting material.  
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Figure II-1. Synthetic scheme of TBA7HDMS. 
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Figure II-2. Synthesis of the tetrabutylammonium salts of hexakis(2,3-di-O-
methyl-6-O-sulfo)-α-CD and octakis(2,3-di-O-methyl-6-O-sulfo)-γ-CD. 
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2.1.1 Synthesis of intermediate I, heptakis(6-O-tert-butyldimethylsilyl)-β-CD 
 The first step consists of the protection of the primary alcohol groups at 
the C6 position.  This is done by reacting native β-CD dissolved in dimethyl 
formamide (DMF) with the silylating agent, tert-butyldimethylchlorosilane 
(TBDMSi-Cl) dissolved in ethyl acetate (EtOAc).  Although protection of the 
hydroxyl group at C6 is selective, undesirable isomeric impurities were formed.  
They were successfully removed by a series of recrystallizations using a ternary 
solvent mixture (DMF/acetone/water) and dried in vacuo.  This first intermediate 
can be obtained with an isomeric purity higher than 99%.   
 
2.1.2 Synthesis of intermediate II, heptakis(2,3-di-O-methyl-6-O-tert-
butyldimethylsilyl)-β-CD 
 The second step consists of the methylation of the hydroxyl groups at the 
C2 and C3 positions.  This is made by reacting intermediate I with iodomethane 
(CH3I) and sodium hydride (NaH) using anhydrous tetrahydrofuran (THF) as the 
reaction solvent.  Once the reaction is completed, sodium iodide (NaI) is 
removed by precipitating it with n-butylacetate (BuOAc) and eventually filtering it 
off. This intermediate can be obtained with a purity higher than 99%. 
 
2.1.3 Synthesis of intermediate III, heptakis(2,3-di-O-methyl)-β-CD 
 The third step consists of the desilylation of intermediate III by removing 
the TBDMSi group from the hydroxyl group at C6.  This is done by dissolving 
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intermediate III in alcohol and hydrofluoric acid (HF).  After the reaction is 
completed, TBDMSi-F is removed and the final product can obtained with a 
purity higher than 99%. 
 
2.1.4 Synthesis of intermediate IV, the sodium salt of heptakis(2,3-di-O-methyl-
6-O-sulfo)-β-CD 
 In the fourth step, the hydroxyl group at C6 is sulfated producing a 
negatively charged cyclodextrin.  This is made by dissolving intermediate IV in 
DMF and reacting it with sulfur trioxide pyridine complex (SO3·Pyr).  In order to 
produce the sodium salt of the product, a slurry of sodium bicarbonate 
(NaHCO3/H2O) is added to the reaction mixture after the reaction is completed.  
Finally, sodium sulfate (Na2SO4) is removed by precipitating it with isopropanol 
(IPA).  This intermediate (Na7HDMS) has been obtained with a purity higher 
than 99%.  
 
2.2 Materials and methods 
 The starting material, Na7HDMS was made in our laboratories using the 
synthetic route reported in Ref. 35.  It was dissolved in a solution that was 
previously made by titrating tetrabutylammonium hydroxide (TBAOH), (Acros 
Organics, Pittsburgh, PA) to pH 7.2 with a solution of 1M hydrochloric acid (HCl), 
(EM Science, Gibbstown, NJ).  After dissolving Na7HDMS in the solution 
mentioned above, the ion exchange was made by several extractions using 
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dichloromethane (CH2Cl2), (EM Science, Gibbstown, NJ) and deionized (DI) 
water obtained from Milli-Q unit (Millipore, Milford, MA). 
 Indirect-UV detection CE (P/ACE 2100 CE system, Beckman-Coulter, 
Fullerton, CA) was used to monitor the removal of the salt (sodium chloride, 
(NaCl)) and to obtain the purity of the final product.  The capillary used was a 
26.4cm total length fused-silica capillary with 27µm internal diameter (Polymicro 
Technologies, Phoenix, AZ) and the detection window at 19.6cm (wavelength at 
214nm) thermostated at 20 oC and 10kV applied potential (positive polarity).  
The BGE used was made by titrating 20mM tris(hydroxymethyl)aminomethane 
(THAM), (EM Science, Gibbstown, NJ) to pH 8.3 with p-toluenesulfonic acid 
(pTSA), (Aldrich Chemical Company, Milwaukee, WI) using DI water as solvent.   
Before using the solutions, they were filtered with a 0.45µm Nalgene nylon 
membrane filter (VWR, South Plaintfield, NJ). 
 For further characterization of the material, 1H NMR spectroscopy was 
used to confirm the completion of ion exchange.  The 1H NMR spectra were 
collected on a Varian Inova 300MHz spectrometer, UNIX based (Varian Assoc., 
Walnut Creek, CA), with a Quad probe for 1H, 13C, 31P and 19F and Solaris 
software (version 2.4) using a SUN workstation.  The sample contained 30mg of 
the final product dissolved in deuterium oxide (D2O), (Cambridge Isotope, 
Andover, MA). 
 The synthesis was first tried on a small scale (1g batch) and after the 
optimum conditions were found, the synthesis was scaled up to 10g and 25g 
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batches.  The same synthesis procedure was also tried with the alpha and the 
gamma CD derivatives on a small scale (1g batch).    
 
2.3 Results and discussion 
2.3.1 Characterization of TBA7HDMS 
 Since the starting material (Na7HDMS) was well characterized by 1H 
NMR, 13C NMR, indirect-UV detection CE and ESI-MS, the characterization of 
the final product (TBA7HDMS) consisted of monitoring the removal of the salt 
(NaCl) produced in the process and monitoring the incorporation of the TBA 
counter ion into the CD. Using indirect-UV detection CE, one can determine the 
purity of the final product and detect the presence of Na+ and TBA+ using 
positive polarity (positive to negative), and the presence of Cl-, using negative 
polarity (negative to positive).  Once sodium is removed (previous counter ion), 
1H NMR was used to confirm that TBA+ was the counter ion of the sulfate group 
in the CD.  This was possible by calculating the ratio of either the protons on the 
methyl group as the C2 or C3 positions of the HDMS7- with protons on the TBA 
group or the ratio between the anomeric protons with the protons on the TBA 
counter ion. 
 The indirect-UV electropherograms and 1H NMR spectra for the three 
different batches (1g, 5g and 25g) are shown in Figures II-3 to II-8.  The 
electropherograms show the EO peak and the presence of TBA+ (no sodium) 
and the presence of HDMS7- in positive mode. They also show the absence of  
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Figure II-3. Indirect-UV detection CE electropherograms of TBA7HDMS  
(1g batch). 
 
 
 
 
 
 
(- to +) 
(+ to -) 
 23
 
 
 
 
Figure II-4. 1H NMR in D2O of TBA7HDMS (1g batch). 
 
 
 
 
 
56.3521.00 56.20 56.46 83.67 
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Figure II-5. Indirect-UV detection CE electropherograms of TBA7HDMS  
(10g batch). 
 
 
 
 
 
(- to +) 
(+ to -) 
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Figure II-6. 1H NMR in D2O of TBA7HDMS (10g batch). 
 
 
 
 
 
56.3621.00 56.21 56.18 83.52 
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Figure II-7. Indirect-UV detection CE electropherograms of TBA7HDMS  
(25g batch). 
 
 
 
 
 
 
(- to +) 
(+ to -) 
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Figure II-8. 1H NMR in D2O of TBA7HDMS (25g batch). 
 
 
 
 
 
56.497.00 56.39 56.10 84.31 
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chloride ions in the final product (negative mode).  On the other hand, the        
1H NMR spectra show that for every HDMS7- there are seven TBA+ molecules.  
In TBA+, there are 36 protons which produce four sets of peaks  
in the 1H NMR spectra, three from the –CH2 and one from the –CH3 (which 
integrate as 8, 8, 8 and 12 protons, respectively).  Since HDMS7- has seven 
TBA+ counter ions the 1H NMR spectra show integration values of 56, 56, 56 
and 84 protons, respectively.   
 
2.3.2 Characterization of the tetrabutylammonium salt of hexakis(2,3-di-O-
methyl-6-O-sulfo)-α-CD  
 The same characterization methods were used for the synthesis of 1g of 
TBA6HxDMS. The indirect-UV detection CE electropherograms in Figure II-9 
show no traces of sodium chloride, but the presence of TBA+ and HxDMS6-.  The 
integration values in the 1H NMR spectra (Figure II-10) for TBA+ are 48, 48, 48 
and 72, which agree with the structure of TBA6HxDMS (HxDMS6- has six TBA+).     
 
2.3.3 Characterization of the tetrabutylammonium salt of octakis(2,3-di-O-
methyl-6-O-sulfo)-γ-CD 
 The synthesis of 1g of TBA8ODMS was also characterized by indirect-UV 
detection CE and 1H NMR spectroscopy.  The electropherograms of the final  
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Figure II-9. Indirect-UV detection CE electropherograms of TBA6HxDMS  
(1g batch). 
 
 
 
 
 
 
 
 
(- to +) 
(+ to -) 
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Figure II-10. 1H NMR in D2O of TBA6HxDMS (1g batch). 
 
 
 
 
 
 
48.20 48.47 48.47 72.01 18.00
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product are shown in Figure II-11 which show the presence of TBA+ and 
ODMS8- with no traces of sodium chloride.  The integration values in the 1H 
NMR spectra (Figure II-12) for the TBA+ are 64, 64, 64 and 96 which confirm the 
incorporation of eight TBA+ counter ions into ODMS8-. 
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Figure II-11. Indirect-UV detection CE electropherograms of TBA8ODMS  
(1g batch). 
 
 
 
 
 
 
(- to +) 
(+ to -) 
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Figure II-12. 1H NMR in D2O of TBA8ODMS (1g batch). 
 
 
 
 
 
  
63.93 64.05 64.35 95.69 24.00
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CHAPTER III 
ENANTIOMER SEPARATIONS IN AQUEOUS CAPILLARY 
ELECTROPHORESIS WITH HEPTAKIS (2,3-DI-O-METHYL-6-O-
SULFO)-β-CYCLODEXTRIN TETRABUTYLAMMONIUM SALT 
 
3.1 Introduction 
 Separations of thirteen selected pharmaceuticals were achieved by CE 
using an aqueous BGE with TBA7HDMS as the chiral resolving agent.  These 
enantiomers can be classified as weak bases, neutral compounds and 
ampholytic compounds (Table III-1).  As mentioned in Chapter I, according to 
the CHARM model, only a low pH and a high pH BGE are needed to obtain the 
best enantiomer separations.  Since single-isomer sulfated CD derivatives have 
been shown to be very successful in the separation of cationic enantiomers, a 
low pH BGE was chosen for the analysis of these particular analytes.  Therefore 
ampholytics, the zwitterions and the weak bases were in their cationic forms as 
protonated species.  Consequently, they had cationic mobilities (positive µeff) at 
zero chiral resolving agent concentration.  The concentration of the chiral 
resolving agent (TBA7HDMS) was increased from 0mM to 50mM.  The effect of 
the concentration of TBA7HDMS on the effective mobility (µeff) of the enantiomer 
and the separation selectivity (α) were studied.  It was observed that the  
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Table III-1. Enantiomers analyzed in aqueous BGE 
Identifier Compound Name Structure 
Biological 
Activity 
Bases    
B21 Isoproterenol 
OH
OH
N
H
OH
β-adrenergic 
agonist 
B22 Ketamine 
O
Cl
NH
 
Anesthetic 
B31 Metoprolol 
O
O
NH
OH
β-blocker 
B34 Norephedrine 
NH2
OH
 
Sympathetic 
nerve-stimulant 
B42 Propranolol 
O
OH
NH
 
β-blocker 
B58 Tetrahydrozoline 
 
Sympathomimetic 
agent with         
α-adrenergic 
activity 
 
 
 
 
N
N
H
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Table III-1. Continued. 
Identifier Compound Name Structure Biological Activity 
Neutrals    
N21 1-Phenylbutanol 
OH  
Percutaneous 
enhancer for 
transdermal drug 
delivery 
N25 1-Phenylpentanol 
OH  
Percutaneous 
enhancer for 
transdermal drug 
delivery 
N26 2-Phenyl-2-pentanol OH
 
Percutaneous 
enhancer for 
transdermal drug 
delivery 
N27 1-Phenyl-2-pentanol 
OH
 
Percutaneous 
enhancer for 
transdermal drug 
delivery 
N28 2-Phenyl-1-propanol 
OH
 
Percutaneous 
enhancer for 
transdermal drug 
delivery 
N38  2-Phenyl-2-butanol 
OH
 
Percutaneous 
enhancer for 
transdermal drug 
delivery 
Ampholyte    
Tryp Tryptophan 
 
Neurotransmitter 
biosynthesis 
precursor 
 
 
 
 
NH2
COOH
NH
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effective mobilities were decreasing as the concentration of the chiral resolving 
agent increased.  This is expected since the viscosity and the ionic strength of 
the BGE increase as the concentration of TBA7HDMS increases, suppressing 
the effective mobilities.  In addition, the complexation constant between the 
analyte and the chiral resolving agent (which carries 7 negative charges) is 
increased as well making the enantiomer less cationic to the point that its 
migration becomes anionic in most of the cases.  In order to find the best 
separation conditions, the effective mobilities and the separation selectivities 
were plotted as a function of the chiral resolving agent concentration.  
 
3.2 Materials and methods 
 The pharmaceuticals used for the enantiomer separation were purchased 
from either Aldrich Chemical Co. (Milwaukee, WI), Sigma (St. Louis, MO), 
Research Diagnostics (Rockdale, MD) or Wiley Organics (Coshocton, OH).  The 
aqueous BGE solutions were made using deionized water obtained from a   
Milli-Q unit (Millipore, Milford, MA).  The buffer components were phosphoric 
acid (H3PO4), obtained from Aldrich Chemical Co. (Milwaukee, WI), and 
tetrabutyl ammonium hydroxide (TBAOH), obtained from Acros Organics, 
Pittsburgh, PA.  The low pH BGE was prepared by titrating 25mM H3PO4 with 
TBAOH to pH 2.5.  Dimethylsulfoxide (DMSO) was used as the EOF marker and 
it was obtained from EM Science (Gibbstown, NJ).  The chiral resolving agent 
used for the enantiomer separation was TBA7HDMS which was made in our 
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laboratories as explained in Chapter II.  The stock buffer solution was used to 
prepare the seven different BGEs by varying the concentration of TBA7HDMS 
from 0mM to 50mM.  Before using the solutions, they were filtered with a 
0.45µm Nalgene nylon membrane filter (VWR, South Plaintfield, NJ). 
 The enantiomer separations were performed using a P/ACE 2100 CE 
instrument indirect-UV detection mode at 214nm wavelength.  The capillary 
used was a 26.4cm total length (19.6cm to detector) fused-silica capillary with 
27µm internal diameter, thermostated at 20 oC.  The pharmaceuticals as well as 
the EOF marker were dissolved in the BGE solution and were co-injected for 1 
second by 5psi nitrogen gas from a solution where both were around 0.5mM in 
concentration.  The potential used was chosen from the linear region of Ohm’s 
plot.  The electroosmotic flow mobility was calculated using equation 1 and the 
DMSO peak as the EOF peak.  On the other hand, the effective mobilities of the 
enantiomers were calculated using equation 2.  In addition, the three-band 
PreMCE method [70] was used when needed, providing the necessary 
information in a shorter analysis time.    
 
3.3 Enantiomer separations in low pH aqueous BGE using TBA7HDMS as the 
chiral resolving agent 
 The results for the separations of the thirteen pharmaceuticals are shown 
in Table III-2.  This table shows the effective mobility (µeff, 10-5cm2/Vs units) of 
the slower enantiomer, the separation selectivity (α) which was calculated using  
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       Table III-2 Enantiomer separations data in low pH aqueous BGE  
5mM TBA7HDMS (15kV) Compound Name μeff α β Rs 
Bases     
Isoproterenol (B21) 1.62 1.89 6.9 2.1 
      
Ketamine (B22) 7.13 1.07 2.0 0.7 
      
Metoprolol (B31) -4.70 0.92 -2.9 0.5 
      
Norephedrine (B34) 5.02 1.22 2.6 1.2 
      
Propranolol (B42) -6.53 0.85 -2.0 2.1 
      
Tetrahydrozoline (B58) 4.69 1.04 2.8 0.3 
Ampholyte     
Tryptophan 0.42 0.00 0.00 0.0 
Neutrals     
1-Phenylbutanol (N21) N/A N/A N/A N/A 
      
1-Phenylpentanol (N25) N/A N/A N/A N/A 
      
2-Phenyl-2-pentanol (N26) N/A N/A N/A N/A 
      
1-Phenyl-2-pentanol (N27) N/A N/A N/A N/A 
      
2-Phenyl-1-propanol (N28) N/A N/A N/A N/A 
      
2-Phenyl-2-butanol (N38) N/A N/A N/A N/A 
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       Table III-2 Continued.  
10mM TBA7HDMS (21kV) Compound Name μeff α β Rs 
Bases     
Isoproterenol (B21) -1.47 0.39 -3.2 2.6 
      
Ketamine (B22) 7.67 1.08 0.6 2.1 
      
Metoprolol (B31) -7.60 0.96 -2.5 1.8 
      
Norephedrine (B34) 1.31 2.24 3.6 3.4 
      
Propranolol (B42) -8.56 0.91 -2.3 4.7 
      
Tetrahydrozoline (B58) 1.16 1.00 16.9 0.0 
Ampholyte     
Tryptophan -0.70 0.76 -11.7 1.5 
Neutrals     
1-Phenylbutanol (N21) -1.31 0.90 -7.5 0.5 
      
1-Phenylpentanol (N25) -0.94 1.00 -9.5 0.0 
      
2-Phenyl-2-pentanol (N26) -3.61 1.00 -3.1 0.0 
      
1-Phenyl-2-pentanol (N27) N/A N/A N/A 0.6 
      
2-Phenyl-1-propanol (N28) -0.55 1.00 -17.3 0.0 
      
2-Phenyl-2-butanol (N38) -0.36 1.00 -24.6 0.0 
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       Table III-2 Continued.  
15mM TBA7HDMS (17kV) Compound Name μeff α β Rs 
Bases     
Isoproterenol (B21) -3.44 0.73 -2.5 10.0 
      
Ketamine (B22) 3.19 1.17 2.7 3.1 
      
Metoprolol (B31) -10.08 N/A -1.0 N/A 
      
Norephedrine (B34) 1.11 1.95 6.7 6.8 
      
Propranolol (B42) -7.06 N/A -1.0 N/A 
      
Tetrahydrozoline (B58) 1.02 1.13 7.2 1.0 
Ampholyte     
Tryptophan -2.21 0.92 -4.0 1.6 
Neutrals     
1-Phenylbutanol (N21) -0.72 0.71 -12.4 0.6 
      
1-Phenylpentanol (N25) -1.31 1.00 -6.7 0.0 
      
2-Phenyl-2-pentanol (N26) -0.49 1.00 -17.5 0.0 
      
1-Phenyl-2-pentanol (N27) -0.50 0.68 -17.4 0.8 
      
2-Phenyl-1-propanol (N28) -0.56 1.00 -15.9 0.0 
      
2-Phenyl-2-butanol (N38) -0.34 1.00 -24.7 0.0 
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       Table III-2 Continued.  
30mM TBA7HDMS (13kV) Compound Name μeff α β Rs 
Bases     
Isoproterenol (B21) -3.33 0.79 -3.4 5.3 
      
Ketamine (B22) 1.89 1.24 3.7 3.8 
      
Metoprolol (B31) -7.89 0.97 -1.5 4.0 
      
Norephedrine (B34) 0.11 9.25 6.2 8.5 
      
Propranolol (B42) -7.07 0.93 -1.6 7.8 
      
Tetrahydrozoline (B58) -1.01 0.90 -11.6 0.8 
Ampholyte     
Tryptophan -2.09 0.95 -5.4 0.9 
Neutrals     
1-Phenylbutanol (N21) -1.13 0.68 -10.3 1.4 
      
1-Phenylpentanol (N25) -2.78 0.82 -2.4 4.3 
      
2-Phenyl-2-pentanol (N26) -0.52 1.00 -21.8 0.0 
      
1-Phenyl-2-pentanol (N27) -0.83 0.74 -13.6 1.4 
      
2-Phenyl-1-propanol (N28) -0.90 1.00 -12.5 0.0 
      
2-Phenyl-2-butanol (N38) -0.52 1.00 -21.8 0.0 
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       Table III-2 Continued.  
40mM TBA7HDMS (10kV) Compound Name μeff α β Rs 
Bases     
Isoproterenol (B21) -3.14 0.79 -3.4 6.5 
      
Ketamine (B22) 1.76 1.29 6.4 2.9 
      
Metoprolol (B31) -6.24 0.97 -1.8 2.8 
      
Norephedrine (B34) -0.82 1.00 -13.8 0.0 
      
Propranolol (B42) -5.54 0.93 -2.0 4.8 
      
Tetrahydrozoline (B58) -0.74 1.00 -15.2 0.0 
Ampholyte     
Tryptophan -1.86 0.95 -4.7 1.0 
Neutrals     
1-Phenylbutanol (N21) -0.99 0.70 -11.3 1.3 
      
1-Phenylpentanol (N25) -1.37 0.76 -8.2 0.7 
      
2-Phenyl-2-pentanol (N26) -0.57 1.00 -16.2 0.0 
      
1-Phenyl-2-pentanol (N27) -0.90 0.74 -10.4 1.5 
      
2-Phenyl-1-propanol (N28) -0.93 1.00 -10.1 0.0 
      
2-Phenyl-2-butanol (N38) -0.55 1.00 -17.3 0.0 
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       Table III-2 Continued.  
50mM TBA7HDMS (10kV) Compound Name μeff α β Rs 
Bases     
Isoproterenol (B21) -2.60 0.79 -1.9 10.2 
       
Ketamine (B22) 1.17 1.31 4.2 4.2 
       
Metoprolol (B31) -2.85 0.97 -1.6 3.5 
       
Norephedrine (B34) -0.98 0.34 -5.0 9.5 
       
Propranolol (B42) -2.10 0.94 -1.7 4.3 
       
Tetrahydrozoline (B58) -0.82 1.00 -5.9 0.0 
Ampholyte     
Tryptophan -1.49 0.95 -5.2 0.6 
Neutrals     
1-Phenylbutanol (N21) -1.20 0.75 -3.8 2.8 
       
1-Phenylpentanol (N25) -1.66 0.81 -2.8 2.0 
       
2-Phenyl-2-pentanol (N26) -0.56 0.85 -13.8 0.7 
       
1-Phenyl-2-pentanol (N27) -0.94 0.76 -8.3 2.0 
       
2-Phenyl-1-propanol (N28) -1.02 0.96 -3.4 0.6 
       
2-Phenyl-2-butanol (N38) -0.68 0.95 -5.1 0.5 
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equation 3, the normalized electroosmotic flow (β) which was calculated using 
equation 4 and the resolution (Rs) which was calculated by dividing the 
difference in peak times in seconds (Δt) with the average of the half height peak 
width of the two enantiomers multiplied by 1.699 (1.699(wR1/2+ wS1/2)/2) at seven 
different TBA7HDMS concentrations (0, 5, 10, 15, 30, 40 and 50mM) with its 
respective applied voltage.  If the enantiomer was not analyzed at a particular 
concentration or a value could not be calculated accurately, an entry of N/A was 
used.   
 Since all the BGEs that were prepared had a pH of 2.5, the six neutral 
enantiomers behaved as neutrals and the six weak bases as well as the 
ampholytic compound behaved as cations at zero TBA7HDMS concentration.  At 
the conditions specified in section 3.1, all thirteen chiral drugs showed some 
separation selectivity.  The best results were obtained for the cationic analytes 
compared to the neutral one. It was expected, since previous work has shown 
that negatively charged single-isomer sulfated β-CD derivatives work better for 
the positively charged analytes than the neutral or negatively charged 
compounds.   
 The weak bases and the ampholytic compound had positive effective 
mobilities (migrated toward the cathode) at 0mM TBA7HDMS.  As the 
concentration of the chiral resolving agent was increased, the effective mobility 
decreased to a value of zero mobility units.  Moreover, further increases in the 
TBA7HDMS concentration resulted in an anionic mobility (migration toward the 
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anode) of the enantiomer.  This may be due to different factors associated with 
the increasing TBA7HDMS concentration such as: i) the ionic strength increases 
causing a decrease in the effective mobilities of the analytes; ii) the viscosity of 
the BGE, which is inversely proportional to the ionic mobility, increases almost 
twice in the 0mM to 50mM range (Figure III-1 and III-2); and iii) complexation 
between the chiral resolving agent and the chiral compound increases making 
the cationic compound to behave more as anionic.  On the other hand, in the 
case of the neutral compounds, they migrated toward the cathode with the 
electroosmotic flow since their effective mobilities are zero in the presence of an 
electric field.  As soon as complexation occurred between TBA7HDMS and the 
enantiomer, the analyte migrated toward the anode (µeff<0) since the new 
diastereomer that was formed was negatively charged.   
 Moreover, the data revealed that there are three different separation 
behaviors that can be observed when separating weak bases and ampholytics.  
The first one is that of the weakly binding analytes which are enantiomers whose 
migration never becomes anionic over the entire TBA7HDMS concentration 
range used.  It is the case of the weak base ketamine (B22) (Figure III-3).  While 
the effective mobility of ketamine decreases approaching a value of zero, the 
separation selectivity increases to a non-limiting value as the concentration of 
TBA7HDMS increases.  The second type is moderately strongly binding analytes 
that are enantiomers that migrate as cations at low chiral resolving agent 
concentrations and migrate as anions at middle to high TBA7HDMS  
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Figure III-1 Contribution of the TBA7HDMS concentration to the viscosity of the 
BGE. 
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Figure III-2. Absolute viscosity of the BGEs at different TBA7HDMS 
concentrations. 
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Figure III-3. Effective mobility (top panel) and separation selectivity plots (bottom 
panel) for the weakly binding analyte ketamine (B22) in low pH aqueous BGE. 
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Figure III-4. Effective mobility (left panels) and separation selectivity plots (right 
panels) for the moderately strongly binding analytes B34and B58 in low pH 
aqueous BGE. 
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concentrations. This is the case for norephedrine (B34) and tetrahydrozoline 
(B58) (Figure III-4). These enantiomers initially migrate as cations and become 
anionic at the 20-25mM TBA7HDMS concentrations.  As a result, their 
separation selectivities increase to an infinitely high value and show a 
discontinuity at a concentration where the enantiomers migrate in the opposite 
directions.  After that point, the separation selectivities increase from negative 
infinite value become positive again and approach unity.  The third type of 
separation is that of the strongly binding analytes which are enantiomers that 
complex with the chiral resolving agent so strongly that they become anionic 
even at a very low TBA7HDMS concentration.  This is the case for three weak 
bases: isoproterenol (B21), metoprolol (B31) and propranolol (B42) and an 
ampholytic compound, tryptophan (Tryp) (Figure III-5). These enantiomers 
became anionic at a concentration around 5mM and remain anionic through the 
entire TBA7HDMS concentration range.  Only isoproterenol (B21) and 
tryptophan (Tryp) had a cationic mobility at 5mM which translates to a 
separation selectivity equal or higher than one at that particular TBA7HDMS 
concentration or below.  After that point, in the separation selectivity pattern 
showed a discontinuity right where the enantiomers started migrating to the 
opposite direction and then the separation selectivity increased from negative 
infinite to unity.  On the other hand, metoprolol (B31) and propranolol (B42) did 
not have cationic mobility through the entire TBA7HDMS concentration range,  
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Figure III-5. Effective mobility (left panels) and separation selectivity plots (right   
panels) for the strongly binding analytes B21, B31, B42 and Tryp in low pH 
aqueous BGE. 
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Figure III-5. Continued. 
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therefore their separation selectivity did not show discontinuity and increased 
from negative infinity to unity. 
In the case of neutral enantiomers, the separation selectivity pattern is 
completely different.  Based on the CHARM model [21], separation selectivity of 
non-charged analytes can be described as follow, 
                                      α = 
[CD]K1
[CD]K1
Kμ
Kμ
RCD
SCD
SCDSCD
o
RCDRCD
o
+
+⋅                                (6) 
 
where µ0RCD and µ0SCD are the ionic mobilities and KRCD and KSCD are the 
complexation constants of the enantiomers.  According to the CHARM model, if 
the concentration of the free enantiomer is much smaller than the concentration 
of the complexed enantiomer, separation selectivity decreases as the 
concentration of the free charged cyclodextrin [CD] increases.  This can be 
observed in Figure III-6, where separation selectivity for 1-phenylbutanol (N25) 
and 1-phenylpentanol (N26) decreases as TBA7HDMS concentration increases. 
 Electropherograms of the separations of the thirteen enantiomers are 
shown in Figure III-7 and Figure III-8.  Resolutions greater than 1.5 (baseline 
separation) were obtained for nine of the thirteen enantiomers and the other four 
were only partially separated.  Each electropherogram shows the structure of the 
analyte, the applied potential (kV) and the TBA7HDMS concentration used for 
that separation.  In some cases the EOF marker (DMSO) appears in the 
electropherogram as well.  In the case of the weak bases and the ampholytic  
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Figure III-6. Separation selectivity plots of N25 and N26 using TBA7HDMS as 
the chiral resolving agent in low pH aqueous BGE. 
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Figure III-7. Electropherograms of weak basic and ampholytic enantiomers at 
low pH aqueous BGE using TBA7HDMS as the chiral resolving agent. 
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Figure III-8. Electropherograms of neutral enantiomers at low pH aqueous BGE 
using TBA7HDMS as the chiral resolving agent. 
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compound, the run time was in the range of three to six minutes with the 
shortest run time at three and a half minutes for the weakly binding ketamine 
(B22) and the longest run time at six minutes for the moderately binding 
tetrahydrozoline (B58). 
 On the other hand, the separation time for the neutral enantiomers was in 
the range of six to thirty one minutes with the shortest run time at six minutes for                      
1-phenylbutanol (N21) and the longest run time at thirty one minutes for            
2-phenyl-2-butanol (N38). 
 
3.4 Comparison of enantiomer separations using TBA7HDMS and Na7HDMS as 
the chiral resolving agent in low pH aqueous BGEs 
 All the thirteen enantiomers separated using TBA7HDMS were previously 
separated using Na7HDMS under the same conditions.  Although, the term 
same conditions refer to the same buffer concentration, same pH, same ionic 
strength and same temperature, the contributions of the two cyclodextrins to the 
viscosity of the BGE were different.  The viscosity of the aqueous BGE for 
TBA7HDMS was twice higher than the viscosity of the aqueous BGE with 
Na7HDMS (Figure III-9 and III-10).  Therefore, all analytes experienced a 
different environment (media) even though both were in aqueous BGEs.  Figure 
III-9 and Figure III-10 show the contributions of the chiral resolving agent to the 
viscosity of the BGE and the absolute viscosity of the BGE for both chiral 
resolving agents, respectively. 
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Figure III-9. Comparison between the contribution of TBA7HDMS and Na7HDMS 
concentration to the viscosity of the BGE. 
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Figure III-10. Comparison of the absolute viscosity of the BGEs at different 
TBA7HDMS and Na7HDMS concentrations. 
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Based on the higher viscosity of the TBA7HDMS BGE, the effective 
mobilities of the enantiomers are expected to be lower (µeff α 1/η).  This is the 
case for the separations of neutral enantiomers; however the effective mobilities 
of the weak bases were slightly higher in the TBA7HDMS BGEs than in 
Na7HDMS BGEs (Figure III-11 and III-12).  Figure III-11 shows the effective 
mobilities and the separation selectivities of some of the neutral enantiomers 
using TBA7HDMS and Na7HDMS as the chiral resolving agent under the same 
conditions.  Figure III-12 shows the effective mobilities and the separation 
selectivities of the ampholytic compound and some of the weak base 
enantiomers using TBA7HDMS and Na7HDMS as the chiral resolving agent 
under the same conditions.  Something interesting can be noticed in           
Figure III-12 and it is the change in binding strength only by changing the 
counter ion of HDMS-7.  For example, isoproterenol (B21) was a weakly binding 
analyte with Na7HDMS, but it became strongly binding analyte with TBA7HDMS.  
In addition, tryptophan (Tryp) which was a moderately binding analyte with 
Na7HDMS, became a strongly binding analyte with TBA7HDMS.  Another two 
enantiomers, norephedrine (B34) and tetrahydrozoline (B58), were weakly 
binding analytes with Na7HDMS and became moderately binding analyte with 
respect to TBA7HDMS.  In general, a trend of increasing binding strength can be 
observed for the seven cationic compounds when a more hydrophobic counter 
ion is used for in the chiral resolving agent.  The opposite was observed for the 
case of the neutral enantiomers. 
 62
 
 
       
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III-11. Comparison of the mobility (left panel) and separation  
selectivity plots (right panel) for N21, (N25), (N26) and (N27) when TBA7HDMS 
and Na7HDMS were used in low pH aqueous BGE. 
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Figure III-12. Comparison of the mobility (left panel) and separation  
selectivity plots (right panel) for isoproterenol (B21), tryptophan (Tryp), 
norephedrine (B34) and tetrahydrozoline (B54) when TBA7HDMS and 
Na7HDMS were used in low pH aqueous BGE. 
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CHAPTER IV 
ENANTIOMER SEPARATIONS IN NON-AQUEOUS CAPILLARY 
ELECTROPHORESIS WITH HEPTAKIS (2,3-DI-O-METHYL-6-O-
SULFO)-β-CYCLODEXTRIN TETRABUTYLAMMONIUM SALT 
 
4.1 Introduction 
 In CE, the solvent used in the BGE plays a very important role in the 
separation of enantiomers.  Different solvents may promote different 
intermolecular interactions that may enhance separation selectivity for the 
enantiomers.  The interest in using solvents other than water has been growing 
in the past few years.  Non-aqueous solvents provide a low conductivity which 
allows the use of higher potential for a faster separation and higher resolution.  It 
also helps in the solubility of the water-insoluble compounds.   
Since Na7HDMS was successfully used for the separation of enantiomers 
in acidic methanolic BGE, the same conditions were used as well with 
TBA7HDMS in order to be able to make comparisons.  Twenty pharmaceuticals 
(Table IV-1) were chosen which include nineteen weak bases and an ampholytic 
compound.  Due to protonation in the acidic methanolic BGE, these enantiomers 
were positively charged at zero chiral resolving agent concentration.  Their 
effective mobilities and separation selectivities as a function of TBA7HDMS 
concentration were studied. 
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Table IV-1 Enantiomers analyzed in non-aqueous BGE. 
Identifier Compound Name Structure Biological Activity 
Bases    
B02 Alprenolol 
 
β-blocker 
B04 Halostachine 
 
β-adrenergic 
agonist 
B11 Bupropion 
 
Antidepressant 
B13 4-Chloroamphetamine 
 
Brain serotonin 
depletion   
B14 Chlophedianol 
 
Antitussive 
B19 Homatropine  Anti-muscarinic 
B21 Isoproterenol 
OH
OH
N
H
OH
 
β-adrenergic 
agonist 
B22 Ketamine 
O
Cl
NH
 
Anesthetic 
B23 Ketotifen  Antihistamine 
B30 Metaproterenol 
 
β-adrenergic 
agonist 
 
N
H
OH
OH
N
Cl
NH2
Cl
O
O
OH
NH
N
H
OH
N
OH
O
O
N
S
O
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Table IV-1. Continued. 
Identifier Compound Name Structure Biological Activity 
Bases    
B31 Metoprolol O
O
NH
OH
 
β-blocker 
B34 Norephedrine 
NH2
OH
 
Sympathetic   
nerve-stimulant 
B36 Oxyphencyclimine  Anticholinergic 
B38 Piperoxan NO
O
 
α-blocker 
B42 Propranolol 
O
OH
NH
 
β-blocker 
B47 Terbutaline 
 
β-adrenergic 
agonist 
B54 Verapamil  Antihypertensive 
B58 Tetrahydrozoline 
 
Sympathomimetic 
agent with         
α-adrenergic 
activity 
B60 Ephedrine 
N
H
OH
 
α&β-adrenergic 
agonist 
Ampholyte    
Tryp Tryptophan 
 
Neurotransmitter 
biosynthesis 
precursor 
 
NH2
COOH
NH
N
N
H
NH2
O
N
N
H
OH
O
O
NH
N
O
O
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4.2 Materials and methods 
 All pharmaceuticals were purchased from either Aldrich Chemical Co. 
(Milwaukee, WI), Sigma (St. Louis, MO), Research Diagnostics (Rockdale, MD) 
or Wiley Organics (Coshocton, OH).  The acidic methanolic buffer was made by 
preparing a solution of 25mM H3PO4 and 12.5mM TBAOH using HPLC grade 
methanol (EM Science (Gibbstown, NJ)) as the solvent.  The stock buffer 
solution was used to prepare eight different BGEs containing 0mM, 0.25mM, 
0.5mM, 1mM, 5mM, 10mM, 25mM and 40mM of TBA7HDMS.  The chiral 
resolving agent, TBA7HDMS was synthesized as explained in Chapter II.  All the 
solutions were filtered with a .45µm Nalgene nylon membrane filter prior to use.  
The enantiomer separations were performed using the same system and 
methodology as explained in Chapter III, with the same capillary specification.  
For the calculation of the electroosmotic flow mobility values (µeo), DMSO was 
used as an EOF marker and naphthalenesulfonic acid (NSA) (Aldrich Chemical 
Co.) was used as an anionic mobility marker, when needed.  The effective 
mobility of NSA was obtained using the three-band PreMCE method [70].  
Ohm’s plot was used to choose the highest possible potential to be used which 
is within the linear region. The effective mobility (µeff), separation selectivity (α), 
normalized electroosmotic flow (β) and resolution (Rs) values were calculated 
for each enantiomer as explained in Chapter III. 
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4.3 Enantiomer separations in acidic methanolic BGE using TBA7HDMS as 
chiral resolving agent 
 The results for the separations of the twenty pharmaceuticals are shown 
in Table IV-2.  This table shows the effective mobility (µeff, 10-5cm2/Vs) of the 
slower enantiomer, the separation selectivity (α), the normalized electroosmotic 
flow (β) and the resolution (Rs) values for each enantiomer at each 
concentration with its respective applied potential.  If the enantiomer was not 
analyzed at a particular concentration or a value could not be calculated 
accurately, an entry of N/A was used.   
 All the enantiomers showed some separation selectivity with the 
exception of two; homatropine (B19) and isoproterenol (B21).  Nine of the 
eighteen enantiomers that were separated had baseline separation (Rs>1.5).  
Typical electropherograms of some of the enantiomers that were separated are 
shown in Figure IV-1.  This figure shows the molecular structure of the 
enantiomer with its identifier, the concentration of TBA7HDMS and the potential 
applied (kV) for that particular electropherogram.  In some cases the EOF 
marker (DMSO) or the anionic mobility marker (NSA) appear in the 
electropherograms as well.  The shortest separation time achieved was one 
minute and a half for the strongly binding ketamine (B22) which occurred at 
0.25mM TBA7HDMS and 25kV applied voltage.  As the concentration of the 
chiral resolving agent is increased, the ionic strength also increases which 
causes a higher conductivity producing more Joule heating.  To avoid this, 
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     Table IV-2.  Enantiomer separation data in acidic methanolic BGE 
0.25mM HDMSTBA (25kV) Compound Name 
μeff α β Rs 
Bases     
Alprenolol (B02)  N/A N/A N/A N/A 
      
Halostachine (B04) N/A N/A N/A N/A 
      
Bupropion (B11) N/A N/A N/A N/A 
      
4-Chloroamphetamine (B13) 3.66 1.00 1.9 0.0 
      
Chlophedianol (B14) N/A N/A N/A N/A 
      
Homatropine (B19) 2.89 1.00 2.6 0.0 
      
Isoproterenol (B21) N/A N/A N/A N/A 
      
Ketamine (B22) 15.04 1.03 0.4 0.4 
      
Ketotifen (B23) -3.37 0.94 -1.9 0.5 
      
Metaproterenol (B30) N/A N/A N/A N/A 
      
Metoprolol (B31) N/A N/A N/A N/A 
      
Norephedrine (B34) N/A N/A N/A N/A 
      
Oxyphencyclimine (B36) N/A N/A N/A N/A 
      
Piperoxan (B38) 6.49 1.00 0.9 0.0 
      
Propranolol (B42) N/A N/A N/A N/A 
      
Terbutaline (B47) N/A N/A N/A N/A 
      
Verapamil (B54) 0.17 2.15 29.8 0.4 
      
Tetrahydrozoline (B58) N/A N/A N/A N/A 
      
Ephedrine (B60) N/A N/A N/A N/A 
Ampholyte     
Tryptophan 2.52 1.00 2.3 0.0 
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              Table IV-2.  Continued 
0.5mM HDMSTBA (25kV) Compound Name 
μeff α β Rs 
Bases     
Alprenolol (B02)  4.28 1.00 2.3 0.0 
      
Halostachine (B04) 2.49 1.00 4.1 0.0 
      
Bupropion (B11) 12.30 1.04 0.8 0.4 
      
4-Chloroamphetamine (B13) -6.04 0.95 -1.7 1.4 
      
Chlophedianol (B14) 2.00 1.00 5.1 0.0 
      
Homatropine (B19) -4.25 1.00 -2.4 0.0 
      
Isoproterenol (B21) 3.35 1.00 3.1 0.0 
      
Ketamine (B22) N/A N/A N/A N/A 
      
Ketotifen (B23) -6.22 1.00 -1.7 0.0 
      
Metaproterenol (B30) 1.60 1.00 6.8 0.0 
      
Metoprolol (B31) 2.54 1.00 4.2 0.0 
      
Norephedrine (B34) 1.36 1.00 4.4 0.0 
      
Oxyphencyclimine (B36) 4.85 1.00 2.1 0.0 
      
Piperoxan (B38) N/A N/A N/A N/A 
      
Propranolol (B42) 0.96 1.25 6.6 1.0 
      
Terbutaline (B47) 2.30 1.06 2.5 0.6 
      
Verapamil (B54) N/A N/A N/A N/A 
      
Tetrahydrozoline (B58) 15.19 1.00 0.4 0.0 
      
Ephedrine (B60) 2.86 1.00 2.2 0.0 
Ampholyte     
Tryptophan N/A N/A N/A N/A 
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              Table IV-2.  Continued 
1mM HDMSTBA (15kV) Compound Name 
μeff α β Rs 
Bases     
Alprenolol (B02)  -10.85 0.96 -0.4 0.6 
      
Halostachine (B04) -14.17 0.97 -0.3 0.7 
      
Bupropion (B11) 3.44 1.26 1.2 2.4 
      
4-Chloroamphetamine (B13) -15.52 1.00 -0.3 0.0 
      
Chlophedianol (B14) -13.46 0.97 -0.3 0.4 
      
Homatropine (B19) -15.46 1.00 -0.3 0.0 
      
Isoproterenol (B21) -10.82 1.00 -0.4 0.0 
      
Ketamine (B22) -17.52 0.98 -0.3 0.0 
      
Ketotifen (B23) -16.25 1.00 -0.3 0.0 
      
Metaproterenol (B30) -10.74 1.00 -0.3 0.0 
      
Metoprolol (B31) -11.15 0.97 -0.5 0.6 
      
Norephedrine (B34) -14.49 1.00 -0.4 0.0 
      
Oxyphencyclimine (B36) -8.96 0.99 -0.6 0.4 
      
Piperoxan (B38) -13.73 0.96 -0.5 2.9 
      
Propranolol (B42) -11.79 0.96 -0.5 2.5 
      
Terbutaline (B47) 0.51 1.00 9.1 0.0 
      
Verapamil (B54) -14.01 0.99 -0.5 1.6 
      
Tetrahydrozoline (B58) 9.06 1.00 0.5 0.0 
      
Ephedrine (B60) -11.67 0.96 -0.4 0.7 
Ampholyte     
Tryptophan -5.94 1.00 -0.4 0.0 
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              Table IV-2.  Continued 
5mM HDMSTBA (15kV) Compound Name 
μeff α β Rs 
Bases     
Alprenolol (B02)  -21.94 0.99 -0.6 0.9 
      
Halostachine (B04) -23.49 0.99 -0.6 0.7 
      
Bupropion (B11) -18.61 1.00 -0.8 0.0 
      
4-Chloroamphetamine (B13) -24.75 1.00 -0.6 0.0 
      
Chlophedianol (B14) -22.26 1.00 -0.6 0.0 
      
Homatropine (B19) -24.15 1.00 -0.6 0.0 
      
Isoproterenol (B21) -22.04 1.00 -0.6 0.0 
      
Ketamine (B22) -17.97 0.99 -0.7 1.8 
      
Ketotifen (B23) -24.13 1.00 -0.5 0.0 
      
Metaproterenol (B30) -21.71 1.00 -0.6 0.0 
      
Metoprolol (B31) -21.90 0.99 -0.5 0.6 
      
Norephedrine (B34) -23.29 1.00 -0.5 0.0 
      
Oxyphencyclimine (B36) -20.96 1.00 -0.6 0.0 
      
Piperoxan (B38) -23.16 0.99 -0.6 1.3 
      
Propranolol (B42) -22.45 0.99 -0.6 0.9 
      
Terbutaline (B47) -21.51 0.99 -0.6 1.2 
      
Verapamil (B54) -23.02 1.00 -0.6 0.0 
      
Tetrahydrozoline (B58) -19.07 0.93 -0.6 3.9 
      
Ephedrine (B60) -23.00 1.00 -0.6 0.0 
Ampholyte     
Tryptophan -18.85 0.99 -0.7 1.8 
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              Table IV-2.  Continued 
10mM HDMSTBA (15kV) Compound Name 
μeff α β Rs 
Bases     
Alprenolol (B02)  -14.49 0.99 -0.4 0.7 
      
Halostachine (B04) -15.71 0.99 -0.3 0.5 
      
Bupropion (B11) -11.40 0.95 -0.5 6.0 
      
4-Chloroamphetamine (B13) -16.51 1.00 -0.3 0.0 
      
Chlophedianol (B14) -14.60 1.00 -0.4 0.0 
      
Homatropine (B19) -15.84 1.00 -0.3 0.0 
      
Isoproterenol (B21) -14.47 1.00 -0.4 0.0 
      
Ketamine (B22) -11.97 0.99 -0.5 1.4 
      
Ketotifen (B23) -15.92 1.00 -0.3 0.0 
      
Metaproterenol (B30) -14.44 1.00 -0.3 0.0 
      
Metoprolol (B31) -14.70 0.99 -0.4 0.8 
      
Norephedrine (B34) -15.68 0.99 -0.4 0.7 
      
Oxyphencyclimine (B36) -13.82 1.00 -0.4 0.0 
      
Piperoxan (B38) -15.51 0.99 -0.4 1.5 
      
Propranolol (B42) -14.77 0.99 -0.4 1.5 
      
Terbutaline (B47) -14.14 0.99 -0.4 1.9 
      
Verapamil (B54) -14.97 1.00 -0.4 0.0 
      
Tetrahydrozoline (B58) -13.31 0.92 -0.4 10.8 
      
Ephedrine (B60) -15.47 1.00 -0.4 0.5 
Ampholyte     
Tryptophan -13.09 0.99 -0.5 2.1 
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    Table IV-2.  Continued 
25mM HDMSTBA (15kV) Compound Name 
μeff α β Rs 
Bases     
Alprenolol (B02)  -10.05 0.99 -0.6 0.9 
      
Halostachine (B04) -10.81 0.99 -0.5 0.7 
      
Bupropion (B11) -8.30 0.96 -0.7 6.6 
      
4-Chloroamphetamine (B13) -11.37 1.00 -0.5 0.0 
      
Chlophedianol (B14) -10.08 1.00 -0.6 0.0 
      
Homatropine (B19) -10.95 1.00 -0.5 0.0 
      
Isoproterenol (B21) -9.99 1.00 -0.6 0.0 
      
Ketamine (B22) -8.52 0.99 -0.7 1.6 
      
Ketotifen (B23) -11.01 1.00 -0.6 0.6 
      
Metaproterenol (B30) -10.16 1.00 -0.6 0.0 
      
Metoprolol (B31) -9.74 0.99 -0.5 0.7 
      
Norephedrine (B34) -10.40 0.99 -0.5 0.9 
      
Oxyphencyclimine (B36) -9.31 1.00 -0.5 0.0 
      
Piperoxan (B38) -10.22 0.99 -0.5 1.5 
      
Propranolol (B42) -10.30 0.99 -0.5 1.2 
      
Terbutaline (B47) -10.50 1.00 -0.5 0.0 
      
Verapamil (B54) -10.60 1.00 -0.5 0.0 
      
Tetrahydrozoline (B58) -9.32 0.92 -0.6 8.2 
      
Ephedrine (B60) -10.83 0.99 -0.5 0.6 
Ampholyte     
Tryptophan -9.23 0.99 -0.6 1.7 
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    Table IV-2.  Continued 
40mM HDMSTBA (15kV) Compound Name 
μeff α β Rs 
Bases     
Alprenolol (B02)  -6.35 0.99 -0.5 1.2 
       
Halostachine (B04) -6.95 0.99 -0.4 0.9 
       
Bupropion (B11) -4.88 0.94 -0.6 7.7 
       
4-Chloroamphetamine (B13) -7.46 1.00 -0.4 0.0 
       
Chlophedianol (B14) -6.40 1.00 -0.5 0.0 
       
Homatropine (B19) -7.03 1.00 -0.5 0.0 
       
Isoproterenol (B21) -6.31 1.00 -0.6 0.0 
       
Ketamine (B22) -4.92 0.99 -0.7 2.4 
       
Ketotifen (B23) -7.33 1.00 -0.7 1.3 
       
Metaproterenol (B30) -6.42 1.00 -0.6 0.6 
       
Metoprolol (B31) -6.51 0.99 -0.7 1.2 
       
Norephedrine (B34) -7.14 0.99 -0.6 1.8 
       
Oxyphencyclimine (B36) -5.70 1.00 -0.5 0.0 
       
Piperoxan (B38) -6.90 0.99 -0.7 2.4 
       
Propranolol (B42) -6.61 0.99 -0.7 2.1 
       
Terbutaline (B47) -6.06 0.98 -0.5 2.2 
       
Verapamil (B54) -6.55 1.00 -0.5 0.0 
       
Tetrahydrozoline (B58) -5.55 0.88 -0.5 15.1 
       
Ephedrine (B60) -6.79 0.99 -0.5 1.2 
Ampholyte      
Tryptophan -5.76 0.99 -0.6 1.7 
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Figure IV-1. Electropherograms of some weak basic and ampholytic 
enantiomers at acidic methanolic BGE using TBA7HDMS as the chiral resolving 
agent 
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Figure IV-1. Continued 
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a lower potential need to be used to be able to stay in the linear region of the 
Ohm’s plot so accurate measurements of effective mobilities can be made.  In 
addition, the viscosity of the BGE also increases if the concentration of the chiral 
resolving agent is increased.  Figure IV-2 and IV-3 show the contribution of the 
cyclodextrin concentration to the viscosity of the BGE and the absolute viscosity 
of the BGE, respectively.  All of these factors (high ionic strength and high 
TBA7HDMS concentration) lead to a lower ionic mobility of the enantiomer.  In 
Figure IV-4, the effective mobility of the enantiomer was plotted as a function of 
TBA7HDMS concentration.  Since all analytes are positively charged at 0mM 
TBA7HDMS, the cationic effective mobility (analyte migrates toward the cathode) 
decreases rapidly as the concentration of TBA7HDMS is increased.  Further 
increase in the TBA7HDMS concentration increases the complexation between 
the enantiomer and the chiral resolving agent which results in the reverse 
migration of the enantiomer: the complex migrates towards the anode (anionic 
mobility) and migration remains anionic through the entire TBA7HDMS 
concentration range.  Although the enantiomer stays anionic after a 
concentration of 3mM TBA7HDMS, the effective mobility of the enantiomer 
decreases with increasing TBA7HDMS concentration. This may be due to the 
higher viscosity of the BGE (µeff α 1/η), and more importantly, to the higher ionic 
strength.  At high TBA7HDMS concentration the ionic strength may suppress the 
dissociation of the tetrabutylammonium counter ion (TBA+) from the CD.  This 
will cause a decrease in the ionic mobility of TBA7HDMS.  In addition, at high  
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Figure IV-2. Contribution of the TBA7HDMS concentration to the viscosity of the  
acidic methanolic BGE. 
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Figure IV-3. Absolute viscosity of the acidic methanolic BGE at different 
TBA7HDMS concentrations. 
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TBA7HDMS concentration the protonated analyte may compete with the counter 
ion of the CD (TBA+) to ion-pair with the CD which is promoted in a non-aqueous 
solvent.   
Optimization of the separation of a strongly binding analyte (in aqueous 
BGE) can be done in NACE since it is typical that non-aqueous BGE weakens 
the binding strength between the analyte and the enantiomer.  However, 
something interesting to be noticed in Figure IV-4 is that all the twenty 
enantiomers studied are strongly binding analytes.  These cationic analytes 
became anionic (migrate toward the anode) at a very low TBA7HDMS 
concentration (as low as 1mM TBA7HDMS) and remain anionic afterward.  The 
effective mobility and the separation selectivity as a function of the TBA7HDMS 
concentration for some of the enantiomers are shown in Figure IV-5 and Figure 
IV-6.  Figure IV-5 shows the effective mobility and separation selectivity as a 
function of TBA7HDMS concentration for two analytes that had cationic mobility 
at a very low TBA7HDMS concentration and became anionic afterward.  The 
separation selectivity increases to an infinitely high value and shows a 
discontinuity when the analyte becomes anionic. After that discontinuity, 
separation selectivity goes through zero, becomes a positive value and finally, 
approaches unity.  On the other hand, Figure IV-6 shows the effective mobility 
and separation selectivity as a function of the TBA7HDMS concentration for two 
enantiomers that were anionic through the entire TBA7HDMS concentration 
range studied.  In this case, only the second part of the separation selectivity 
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Figure IV-4. Effective mobilities as a function of TBA7HDMS concentration for all 
the twenty enantiomers which are strongly binding analytes.  
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Figure IV-5. Effective mobility (left panels) and separation selectivity plots (right 
panels) of 4-chloroamphetamine (B13) and ketotifen (B23) when TBA7HDMS 
was used in acidic methanolic BGE. 
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Figure IV-6. Effective mobility (left panels) and separation selectivity plots (right 
panels) of propranolol (B42) and verapamil (B54) when TBA7HDMS was used in 
acidic methanolic BGE. 
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curve is seen, indicating the change for negative infinity to a positive value that 
approaches unity. 
 
4.4 Comparison of enantiomer separations using TBA7HDMS as chiral resolving 
agent in aqueous and acidic methanolic BGEs 
  Seven of the twenty enantiomers that were analyzed in acidic methanolic 
BGE using TBA7HDMS as the chiral resolving agent were also separated in 
aqueous BGE.  Weaker binding strength in NACE is typical; however all the 
enantiomers analyzed in the acidic methanolic BGE were strongly binding 
analytes.  With the exception of tetrahydrozoline (B58) (Rs=1, β=7.2), all the 
analytes were baseline separated (Rs>1.5) in the aqueous BGEs.  On the other 
hand, B58 had the highest resolution (Rs=15.1) in NACE where the normalized 
electroosmotic flow was much better (β=-0.5).  Moreover, isoproterenol (B21) 
which was baseline separated at all TBA7HDMS concentrations in aqueous 
BGE, did not show any separation selectivity in NACE, even with a better β 
value.  In general, NACE provided a better β and in most cases a better α; 
however the best separation results (highest Rs) were obtained using aqueous 
BGE with the exception of B58. 
 Effective mobility and separation selectivity as a function of the 
TBA7HDMS concentration for ketamine (B22) in NACE and in aqueous BGE are 
shown in Figure IV-7.  The analyte that is weakly binding in aqueous BGE 
became a strongly binding analyte in NACE.  Although the β value in NACE was 
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Figure IV-7. Comparison of the mobility plots (top panel) and separation 
selectivity (bottom panel) for ketamine (B22) when TBA7HDMS was used in 
aqueous and non-aqueous BGEs. 
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more favorable, the separation selectivity in aqueous BGE was so high that it 
lead to a higher resolution compared to NACE. 
Norephedrine (B34) and tetrahydrozoline (B58), which were moderately binding 
analytes in aqueous BGE, became strongly binding analytes in NACE (Figure 
IV-8).  It is clear that the separation selectivity for B34 in aqueous BGE was 
more favorable in comparison to NACE.  Even with a β of negative five, the 
resolution was nine and a half in the aqueous BGE in comparison to a very good 
β of negative one half and a resolution of almost two in NACE.  On the other 
hand, the separation selectivity for B58 was almost the same in the aqueous 
BGE and the acidic methanolic BGE, but the better β value (β=-0.5) in NACE 
made the difference with a resolution of fifteen in comparison to a resolution of 
one in aqueous BGE (β=7.2).   
 Finally, the last four compounds to be discussed were the ones that were 
strongly binding analytes in both the aqueous and non-aqueous BGEs.  Even 
though all the analytes are strongly binding analytes in both BGEs, they became 
anionic at a lower TBA7HDMS concentration (1mM) in NACE than in aqueous 
BGE     (5-7mM TBA7HDMS) (Figure IV-9).  Figure IV-9 clearly shows how the 
separation selectivity for all four enantiomers is better in aqueous BGE than in 
NACE.  Only two enantiomers were baseline separated in both the aqueous and 
non-aqueous BGEs (propranolol (B42) and tryptophan (Tryp)).  That was not the 
case for metoprolol (B31) which was baseline separated in the aqueous BGE,  
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Figure IV-8. Comparison of the mobility (top panel) and separation selectivity 
plots (bottom panel) for norephedrine (B34) and tetrahydrozoline (B58) when 
TBA7HDMS was used in aqueous and non-aqueous BGEs.  
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Figure IV-9. Comparison of the mobility (top panel) and separation selectivity 
plots (bottom panel) for isoproterenol (B21), metoprolol (B31), propranolol (B42) 
and tryptophan (Tryp) when TBA7HDMS was used in aqueous BGE and non-
aqueous BGEs. 
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but only partially separated in NACE despite the very good β value (β=-0.7).  A 
totally opposite scenario was obtained for isoproterenol (B21) which was 
baseline separated at all TBA7HDMS concentrations in the aqueous BGE and 
did not show any separation selectivity at any of the TBA7HDMS concentrations 
in NACE.  
 
4.5 Comparison of enantiomer separations using TBA7HDMS and Na7HDMS as 
chiral resolving agents in acidic methanolic BGE 
Six of the twenty pharmaceuticals separated using TBA7HDMS were 
previously separated using Na7HDMS.  To be able to make any comparison, 
both enantiomer separations were performed at the same temperature, buffer 
concentration, ionic strength and pH.  However, the contribution of the CD to the 
viscosity of the BGE is different, which provides two different media for the 
separation to take place.  Figure IV-10 and Figure IV-11 show the contribution of 
both CDs to the viscosity of the non-aqueous BGE and the absolute viscosity of 
the non-aqueous BGE with both CDs, respectively.  The TBA7HDMS BGE 
showed a higher viscosity than the Na7HDMS BGE as expected since that was 
the case in the aqueous BGE.  A higher viscosity is expected to lead to a lower 
effective mobility in that BGE; however the highest effective mobilities for the six 
enantiomers with TBA7HDMS are in the range of -18 to -25 mobility units in 
comparison to 8 to -4 mobility units with Na7HDMS. 
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Figure IV-10. Comparison between the contribution of TBA7HDMS and  
Na7HDMS concentration to the viscosity of the non-aqueous BGE. 
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Figure IV-11. Comparison of the absolute viscosity of the non-aqueous BGEs at   
different TBA7HDMS and Na7HDMS concentrations. 
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Figure IV-12. Comparison of the mobility (top panel) and separation selectivity 
plots (bottom panel) for isoproterenol (B21), metaproterenol (B30), 
oxyphencyclimine (B36) and propranolol (B42) when TBA7HDMS and Na7HDMS 
were used in NACE.  
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On the other hand, four of the six enantiomers were weakly binding 
analytes using Na7HDMS and became strongly binding analytes when 
TBA7HDMS was used (Figure IV-12). Figure IV-12 shows the effective mobilities 
of isoproterenol (B21), metaproterenol (B30), oxyphencyclimine (B36) and 
propranolol (B42) as a function of the concentration of the chiral resolving agent.  
When Na7HDMS was used all analytes had a cationic mobility (migrated toward 
the cathode), through the entire Na7HDMS concentration range.  On the other 
hand, when TBA7HDMS was used, the cationic mobility of the analytes became 
anionic at a very low TBA7HDMS concentration (1mM TBA7HDMS) and 
remained anionic with further increase in the TBA7HDMS concentration.   
Since all twenty enantiomers became strongly binding analytes when 
TBA7HDMS was used, the separation selectivity may not be favorable in 
comparison with the use of Na7HDMS that led to some weakly binding analytes, 
some moderately binding analytes and no strongly binding analytes.  Separation 
selectivity may not be favorable for strongly binding analytes because the chiral 
resolving agent may complex so strongly with both enantiomers (R and S) that 
chiral recognition may not be observed (no selectivity, α=1) and the mobility 
differences between the new diastereomers may not be significant.  The 
separation selectivity as a function of the CD concentration for the four analytes 
that were weakly binding to Na7HDMS and strongly binding to TBA7HDMS are 
shown in Figure IV-12.  It is very clear that separation selectivities for the 
enantiomers separated using Na7HDMS are much better than those obtained 
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using TBA7HDMS which only shows separation selectivity different from one for 
two enantiomers out of the four.  Those enantiomers that did not show any 
separation selectivity using TBA7HDMS were isoproterenol (B21) and  
metaproterenol (B30), which were baseline separated at all Na7HDMS 
concentrations (Rs>1.5).   
In the case of the two enantiomers that were moderately binding to 
Na7HDMS and strongly binding to TBA7HDMS, the separation selectivity was 
also favorable using Na7HDMS (Figure IV-13).  Both enantiomers were baseline 
separated at all Na7HDMS concentrations in contrast with the results obtained 
by TBA7HDMS where both were only partially separated (Rs<1.5).  
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Figure IV-13.  Comparison of the mobility (top panel) and separation selectivity 
plots (bottom panel) for 4-chloroamphetamine (B13) and ketotifen (B23) when 
TBA7HDMS and Na7HDMS were used in NACE. 
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CHAPTER V 
CONCLUSIONS 
 
Synthesis of a sulfated CD (TBA7HDMS) highly soluble in organic solvent 
was obtained by adding one more step to the reported synthetic route of 
Na7HDMS.  This step consisted of an extraction of TBA7HDMS with 
dichloromethane from an aqueous solution containing Na7HDMS and TBACl.  
The synthesis of TBA7HDMS was scaled up from 1g batch to 25g batch using 
the well characterized single-isomer Na7HDMS as the starting material.  The 
procedure turned out to be fairly easy, so it was also tried with the sodium salt of 
hexakis(2,3-di-O-methyl-6-O-sulfo)-α-cyclodextrin and the sodium salt of octakis 
(2,3-di-O-methyl-6-O-sulfo)-γ-cyclodextrin yielding the expected results as 
TBA7HDMS.  All three single-isomers sulfated CDs were characterized by 
indirect-UV detection CE and NMR spectroscopy which provided the necessary 
information to confirm the proposed structures with purities higher than ninety 
seven percent. 
Separations of thirteen pharmaceuticals were achieved using CE as the 
separation technique in an aqueous BGE.  The low pH aqueous BGE contained 
25mM phosphoric acid buffered to pH 2.5 using TBAOH.  It also contained 
TBA7HDMS which was the chiral resolving agent.  The potential used was 
chosen to be within the linear region of Ohm’s law plots.  Effective mobilities and 
separation selectivities as a function of the TBA7HDMS concentration were 
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plotted.  The effective mobility and the separation selectivity trends for the weak 
bases and the neutrals enantiomers followed the predictions of the CHARM 
model.  Based on these trends, the weak bases and the ampholytic compound 
were categorized into three binding strength groups: i) strongly binding analytes; 
ii) moderately strongly binding analytes and; iii) weakly binding analytes.  These 
enantiomers were baseline separated with the exception of tetrahydrozoline 
(B58) which was only partially separated.  In the case of the neutral 
enantiomers, only three of the six were baseline separated.  In most cases, the 
separation selectivities appeared at high TBA7HDMS concentrations (30mM) in 
contrast to the weak bases and the ampholytic compound which were separated 
at 5mM TBA7HDMS. 
Comparisons between chiral resolving agents (TBA7HDMS and 
Na7HDMS) were made in aqueous BGE.  The binding strength of the weak 
bases and the zwitterion increased when TBA7HDMS was used.  In addition, 
TBA7HDMS provided better separation selectivities for the weak bases and the 
zwitterion in comparison to the one obtained with Na7HDMS.  On the other hand, 
comparable results in the separation selectivities of the neutral enantiomers 
were achieved for both chiral resolving agents. 
TBA7HDMS was also used for the separation of twenty pharmaceuticals 
in acidic methanolic BGEs.  The effective mobilities and separation selectivities 
as a function of TBA7HDMS were also plotted.  Surprisingly, all the enantiomers 
became strongly binding analytes with very similar mobility trends.  This may 
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suggest that the binding strength is independent of the molecular structure of the 
enantiomer under these particular conditions.  Nine of the eighteen analytes 
were baseline separated and the rest were partially separated with the exception 
of homatropine (B19) and isoproterenol (B21).  The highest resolution (Rs=15.1) 
was obtained for tetrahydrozoline (B58) which was only partially separated 
(Rs=1) in aqueous BGE.  Overall, separation selectivities in the aqueous BGEs 
were more favorable than in the acidic methanolic BGEs using TBA7HDMS in 
both. 
Comparison between TBA7HDMS and Na7HDMS were made for the 
separations in non-aqueous BGEs.  Four enantiomers (isoproterenol (B21), 
metaproterenol (B30), oxyphencyclimine (B36) and propranolol (B42)) that were 
weakly binding analytes using Na7HDMS became strongly binding analytes 
using TBA7HDMS.  The separation selectivities for these analytes using 
Na7HDMS were more favorable than the ones obtained using TBA7HDMS.  In 
addition, two moderately binding analytes (4-chloroamphetamine (B13) and 
ketotifen (B23)) when Na7HDMS was used, became strongly binding analytes 
when TBA7HDMS was used.  More favorable separation selectivities were 
obtained when Na7HDMS was used allowing baseline separation at all 
Na7HDMS concentrations.  On the other hand, only partial separation was 
obtained for these two enantiomers when TBA7HDMS was used. 
In conclusion, changing the inorganic counter ion of sodium in Na7HDMS 
to a hydrophobic counter ion tetrabutylammonium (TBA+), not only improved the 
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solubility of the HDMS7- in the non-aqueous solvent, but it also resulted in an 
increased binding strength when comparison of the same analytes using 
TBA7HDMS and Na7HDMS were made.  Therefore, different separation 
selectivity patterns were obtained which were in some cases more favorable for 
the separation of enantiomers using TBA7HDMS (i.e., aqueous BGEs) and in 
other cases, more favorable when Na7HDMS was used (i.e., NACE). 
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APPENDIX A 
 
SYNTHESIS PROTOCOL FOR TBA7HDMS 
 
 
Synthesis of the tetrabutylammonium salt of heptakis (2,3-di-O-methyl-6-O-
sulfo)-β-CD (TBA7HDMS) from the sodium salt of heptakis (2,3-di-O-methyl-6-O-
sulfo)-β-CD (Na7HDMS).   
Materials needed for 25g scale: 
Na7HDMS: 
mNa7HDMS = 25g Na7HDMS (MWNa7HDMS = 2045.69g/mol) 
TBAOH 40%w/w in water (MWTBAOH = 259.46g/mol; ρTBAOH = 0.99g/mL): 
VTBAOH = nNA7HDMS x 7 x 1.05 x MWTBAOH x (100/40%)/ρTBAOH = 59mL 
Deionized (DI) water 
Hydrochloric acid (HCl) 
Dichloromethane (CH2Cl2) 
Procedure: 
1.  Add the 59mL of 40%w/w TBAOH into a 250mL beaker with a 2” flat-shape 
teflon coated stri-bar.  Place the beaker onto a stir-plate.   
2.  Start stirring the solution. Using a calibrated pH-meter, add the necessary 
amount of HCl to adjust the pH to 7.0-7.2 (pH can not be lower than 7.0).  
3.  Add 25g of Na7HDMS into the beaker while stirring the TBACl solution.  It 
may take fifteen to thirty minutes to dissolve the solid. 
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4.  Once a homogeneous solution is obtained, measure the volume.  Pour the 
reaction mixture into a 1L separatory funnel.  Add the same volume of CH2Cl2.  
Shake the separatory funnel and wait until the organic phase (at the bottom) and 
aqueous phase (at the top) get separated.  Dispose the aqueous phase 
(containing NaCl). 
5.  Measure the volume of the organic phase.  Add the organic phase back to 
the separatory funnel with an equal volume of DI water.  Shake the separatory 
funnel and wait until the phases get separated.  Dispose the aqueous phase. 
6.  Transfer the organic phase to a 1L round-bottom flask with 2” football-shaped 
teflon coated stir-bar.  Using a rotovap, remove the solvent (CH2Cl2) at 50°C. 
7.  To confirm the removal of NaCl, use an indirect-UV detection CE.  Prepare 
the background electrolyte (BGE) with 25mM TRIS and 12.5mM pTSA (pH 8.3). 
Weigh 20mg of the final product and dissolve it in 5mL of BGE.  All the solution 
must be filter with 0.45µm nylon-membrane before use.  Use a fused-silica 
capillary 26cm total length and detection window at 19cm (wavelength 214nm).  
Carry out the analysis at 20°C using potential of 10kV.  Use a negative polarity 
at the detector to check for the removal of Na+, the presence of TBA+ and the 
purity of the HDMS7-.  To check for the removal of Cl- use a positive polarity at 
the detector.  If NaCl is detected, repeat step 5. 
8.  To look for the ratio of TBA+ and HDMS7- (7:1) use 1H NMR.  Dissolve 30mg 
of the final product in D2O.  Pour the solution in an NMR tube until 5cm of the 
tube are filled with the sample. 
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